News | November 03, 2021
Venus Remedies H1 net profit rises 315%
Venus Remedies has reported consolidated financial results for the period ended September 30, 2021
Venus Remedies has reported consolidated financial results for the period ended September 30, 2021
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
The company claims that its Empagliflozin tablets are the most affordable in India
This new lyophilizer is equipped with systems to best protect high value Active Pharmaceutical Ingredients (APIs) and doubles the lyophilization capacity at the site
The drug is being developed at lab scale for the first-line of treatment of Covid-19
According to IQVIA, US sales of Everolimus (Afinitor) tablets were approximately US $ 675 million in the 12 months ending July 2021
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
The investment programme is expected to significantly reduce commercialisation lead times, costs and introduce more sustainable manufacturing processes
They enter into exclusive negotiations in a new drive to create a technology-driven leader for complex small molecules and ADCs of global scale
Subscribe To Our Newsletter & Stay Updated
